The University of Pittsburgh (Pitt) and Bayer have collaborated to advance research for heart, lung and blood disease indications.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The partnership spans from early research studies to drug development and big data analysis, including real-world evidence studies.

Bayer will also support an independent investigator-initiated clinical trial in sickle-cell disease.

University of Pittsburgh School of Medicine chair of the department of medicine Mark Gladwin said: "The alliance builds upon a productive history of research collaboration between the scientists at Pitt and Bayer.

“Working with Bayer under this master agreement will allow us to further explore drug discovery research to better understand and meet patient needs.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The collaboration will be managed by a committee comprising leaders from Bayer and the university.

"Working with Bayer under this master agreement will allow us to further explore drug discovery research to better understand and meet patient needs."

It will also manage and make ongoing decisions to govern the joint research activities.

Bayer senior vice-president and head of medical affairs Dario Mirski said: "Bayer is proud to partner with the University of Pittsburgh, bringing together their renowned scientists in partnership with Bayer's clinical disease experts and in-depth expertise in delivering new therapies to patients.

"Our goal is to advance meaningful research around pathophysiology and discovery, working closely with Pitt to evaluate new therapeutic principles for heart, lung and blood diseases."

The University of Pittsburgh School of Medicine integrates new technology with basic science across various disciplines to harness the power of new knowledge.


Image: A committee comprising leaders from Bayer and Pitt will make ongoing decisions to govern the joint research activities. Photo: courtesy of Patricia Yliniemi / FreeImages.com.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact